Channel Therapeutics CORP 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Pelthos Therapeutics Inc. reports a net loss of $43.3 million for 2025, driven by commercialization efforts for ZELSUVMI and recent acquisitions of XEPI and XEGLYZE, while securing $30 million in new financing.
Channel Therapeutics Corporation files its 2024 10-K, detailing financial results and providing updates on its pain management therapeutic programs.
Chromocell Therapeutics Corporation's 2023 10-K filing highlights its focus on developing non-opioid pain treatments, including CC8464 for neuropathic pain and CT2000 for eye pain, while also expanding its pipeline through strategic licensing.